摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[2-(2-methoxyethoxy)-5-phenyl-furo[2,3-d]pyrimidin-4-yl]-pyridin-2-ylmethylamine | 871814-98-1

中文名称
——
中文别名
——
英文名称
[2-(2-methoxyethoxy)-5-phenyl-furo[2,3-d]pyrimidin-4-yl]-pyridin-2-ylmethylamine
英文别名
2-(2-methoxyethoxy)-5-phenyl-N-(pyridin-2-ylmethyl)furo[2,3-d]pyrimidin-4-amine
[2-(2-methoxyethoxy)-5-phenyl-furo[2,3-d]pyrimidin-4-yl]-pyridin-2-ylmethylamine化学式
CAS
871814-98-1
化学式
C21H20N4O3
mdl
——
分子量
376.415
InChiKey
OVSXQHNSAWRCHB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    28
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    82.3
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

  • 作为产物:
    参考文献:
    名称:
    [EN] FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS
    [FR] COMPOSES DE FURANOPYRIMIDINE EFFICACES COMME INHIBITEURS DES CANAUX POTASSIQUES
    摘要:
    式(I)的化合物,其中R1为芳基、杂环芳基、环烷基或烷基;R2为H、烷基、硝基、-CO2R7、CONR4R5或卤素;R3为H、NR4R5、NC(O)R8、卤素、三氟甲基、烷基、腈基或烷氧基;R4和R5可以相同也可以不同,可以是H、烷基、芳基、杂环芳基或环烷基;或者R4和R5可以共同形成饱和、不饱和或部分饱和的4到7成员环,其中该环可以选择性地包含一个或多个来自N、O或S的其他杂原子;X为O、S或NR6;R6为H或烷基;R7为氢、甲基或乙基;R8为甲基或乙基;Ll为(CH2)n,其中n为1、2或3;Y为芳基、杂环基、烷基、烯基或环烷基;以及其药学上可接受的盐。还描述了这些化合物作为钾通道抑制剂的用途。
    公开号:
    WO2005121149A1
点击查看最新优质反应信息

文献信息

  • Furanopyrimidine compounds as potassium ion channel inhibitors
    申请人:Ford John
    公开号:US20050282829A1
    公开(公告)日:2005-12-22
    A compound of formula (I) wherein R 1 is aryl, heteroaryl, cycloalkyl or alkyl; R 2 is H, alkyl, nitro, —CO 2 R 7 , CONR 4 R 5 or halo; R 3 is H, NR 4 R 5 , NC(O)R 8 , halo, trifluoromethyl, alkyl, nitrile or alkoxy; R 4 and R 5 may be the same or different, and may be H, alkyl, aryl, heteroaryl or cycloalkyl; or R 4 and R 5 may together form a saturated, unsaturated or partially saturated 4 to 7 member ring, wherein said ring may optionally comprise one or more further heteroatoms selected from N, O or S; X is O, S or NR 6 ; R 6 is H or alkyl; R 7 is hydrogen, methyl or ethyl; R 8 is methyl or ethyl; L is (CH 2 ) n , where n is 1, 2 or 3; and Y is aryl, a heterocyclic group, alkyl, alkenyl or cycloalkyl; together with pharmaceutically acceptable salts thereof. The use of these compounds as potassium channel inhibitors is also described.
    化合物的结构式为(I),其中 R1为芳基,杂环芳基,环烷基或烷基; R2为,烷基,硝基,—CO2R7,CONR4R5或卤素; R3为,NR4R5,NC(O)R8,卤素,三甲基,烷基,腈基或烷基; R4和R5可以相同也可以不同,可以是,烷基,芳基,杂环芳基或环烷基;或者R4和R5可以共同形成饱和的、不饱和的或部分饱和的4至7成员环,其中该环可以选择性地包含一个或多个来自N、O或S的进一步杂原子; X为O、S或NR6; R6为或烷基; R7为甲基或乙基; R8为甲基或乙基; L为(CH2)n,其中n为1、2或3; Y为芳基、杂环基、烷基、基或环烷基; 以及其药学上可接受的盐。同时也描述了这些化合物作为通道抑制剂的用途。
  • FURANOPYRIMIDINE COMPOUNDS EFFECTIVE AS POTASSIUM CHANNEL INHIBITORS
    申请人:Xention Limited
    公开号:EP1758909A1
    公开(公告)日:2007-03-07
  • US7456187B2
    申请人:——
    公开号:US7456187B2
    公开(公告)日:2008-11-25
查看更多

同类化合物

呋喃并[2,3-d]嘧啶-4(1H)-酮 呋喃并[2,3-d]嘧啶-2(3H)-酮 呋喃并[2,3-d]嘧啶 6-苯基呋喃并[2,3-D]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4-胺 6-甲基呋喃并[2,3-d]嘧啶-4(3H)-酮 6-(4-甲氧基苯基)呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲氧基苯基)-5-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-甲基苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(4-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(4-氯苯基)-呋喃并[2,3-d]嘧啶-4-胺 6-(3-溴-苯基)-4-氯-呋喃并[2,3-d]嘧啶 6-(3-吡啶)-呋喃并[2,3-d]嘧啶-4-胺 5-甲基呋喃并[2,3-d]嘧啶-4-胺 5-溴呋喃并[2,3-D]嘧啶-4-胺 5-氯甲基呋喃并[2,3-d]嘧啶-2,4-二胺 5,6-二甲基呋喃[2,3-d]嘧啶-4-胺 4-氯呋喃[2,3-D]嘧啶 4-氯-6-甲基-呋喃并[2,3-d]嘧啶 4-氨基呋喃并[2,3-D]嘧啶 4,6-二甲基呋喃并[2,3-d]嘧啶 4,6-二甲基呋喃并[2,3-D]嘧啶-2-胺 3-(2-脱氧-beta-D-赤式-呋喃戊糖基)-6-甲基呋喃并[2,3-d]嘧啶-2(3H)-酮 2-甲基硫代呋喃并[2,3-d]嘧啶-6-甲醇 2,4-二氯呋喃并[2,3-d]嘧啶 2,4-二氯-5-甲基呋喃并[2,3-d]嘧啶 2-Methyl-4-diacetylamino-5,6-bis-(2-furyl)furo<2,3-d>pyrimidine 3-[1-methyl-6-(5-nitro-furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino]-propan-1-ol 1-Methyl-4-(1-methyl-2-methoxy-ethyl-amino)-6-(5-nitro-2-furyl)-1H-pyrazolo<3.4-d>pyrimidin 2-Ethyl-4-amino-5,6-bis-(2-furyl)furo<2,3-d>pyrimidine 3-[3’,5’-di-O-(tert-butyldimethylsilyl)-2’-deoxy-β-D-ribofuranosyl]-6-(p-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 2,6-dimethyl-3H-furo[2,3-d]pyrimidine-4-thione 4-hydrazino-6-methyl-2-phenyl-furo[2,3-d]pyrimidine 3-[3'-O-(tert-butyldimethylsilyl)-2'-deoxy-β-D-ribofuranosyl]-6-(p-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one 4-Ethylamino-6-methylfuro<4,5-b>pyrimidin 6-[Diethoxy(oxido)phosphaniumyl]furo[2,3-d]pyrimidine t counted 4-methoxy-2,6-dimethyl-furo[2,3-d]pyrimidine 3-(2-deoxy-β-D-erythro-pentofuranosyl)-6-ethynyl-furo[2,3-d]pyrimidin-2(3H)-one ethyl (4-oxo-5-phenyl-3,4-dihydrofuro[2,3-d]pyrimidin-2-yl)acetate 2,2'-[3-methyl-6-(5-nitro-furan-2-yl)-isoxazolo[5,4-d]pyrimidin-4-ylazanediyl]-bis-ethanol 5-[(R/S)-2-(2'-methoxyphenyl)pentyl]furo[2,3-d]pyrimidine-2,4-diamine 5-acetyl-6-(benzyloxy)-2,4-dimethylfuro<2,3-b>pyridine 5-[(R/S)-2-(2'-methoxyphenyl)-3-methylbutyl]furo[2,3-d]-pyrimidine-2,4-diamine furan-2-carboxylic acid N'-{2-amino-7-[2-(t-butyldimethylsilanyloxy)ethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-hydrazide 2-(5-phenylfuro[2,3-d]pyrimidin-4-ylamino)ethanol 5-[(R/S)-2-(2'-methoxyphenyl)-4-methylpentyl]furo[2,3-d]pyrimidine-2,4-diamine 5-[(R/S)-2-(2'-methoxyphenyl)hexyl]furo[2,3-d]pyrimidine-2,4-diamine tert-butyl 3-<6'-(benzyloxy)-2',4'-dimethylfuro<2,3-b>-pyrid-5'-yl>-3-hydroxybutanoate 6-(benzyloxy)-2,4-dimethylfuro<2,3-b>pyridine-5-carboxaldehyde